A recombinant AAVrh74 gene therapy expressing the dysferlin transgene under control of a muscle-specific promoter (rAAVrh74.MHCK7.DYSF.DV).
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.